1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Regulation

FDA Withdraws Direct-To-Consumer Ad Guidance, As It Develops Social Media Documents

Agency reps updated stakeholders on guidance development efforts related to advertising and promotion during a Food and Drug Law Institute conference in Washington, D.C.

FDA is working to develop several new guidance documents related to advertising and promotion of medical products, focusing on use of social media in particular, while the agency has also withdrawn longstanding draft guidance on device-specific consumer advertising.

On Sept. 28, the agency withdrew its direct-to-consumer (DTC) marketing guidance, entitled “Consumer-Directed Advertising of Restricted Devices,” which was released in draft form in 2004 and addresses TV, radio and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation

EU Finalizes Framework For Joint Clinical Assessments Of High-Risk Devices

 
• By Amanda Maxwell

Second submission window for joint scientific consultations on a procedure to help prepare for joint clinical assessments will open from 2 to 30 June 2025.

Get Ready For International Harmonization Before Approaching QMSR Deadline, Says Regulatory Expert

 
• By Brian Bossetta

During MD&M East last week, regulatory consultant Darren Reeves reminded device manufacturers that the time to get ready to comply with the new Quality Management System Regulation is now.

UK Take Care! Regulatory And Market Access Reforms Must Not Shut Out Medtech Growth

 
• By Ashley Yeo

Speakers at a recent UK medtech outlook conference voiced optimism about the sector’s prospects, but warned that cost burdens, over-regulation and lengthy processes will impede the capacity of local SMEs to innovate. Only 10% of NHS procured medtech comes from UK manufacturers.